ReviewImmunological investigations2018
Myeloid-Derived Suppressor Cells at the Intersection of Inflammaging and Bone Fragility.
Review in Immunological investigations, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 33 citations in OpenAlex.
- Gut microbiota transmits osteoimmune dysregulation and exacerbates trabecular bone loss in tristetraprolin-deficient mice.Journal of bone and mineral metabolism · 2026Article
- Immune reprogramming in the bone marrow microenvironment: a new perspective on the bone immune microenvironment of postmenopausal osteoporosis.Frontiers in immunology · 2026Review
- From Development, Disease, and Decline: A Review of What Defines an Osteoclast Progenitor.International journal of molecular sciences · 2025Review
- Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- COX-2 inhibition as a therapeutic strategy for bone loss in Staphylococcus aureus osteomyelitis.Molecular medicine (Cambridge, Mass.) · 2025Article
- Fractures Associated with Immune Checkpoint Inhibitors: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Single-cell transcriptomics identifies the common perturbations of monocyte/macrophage lineage cells in inflammaging of bone marrow.Journal of orthopaedic translation · 2025Article
- Innate Immunity and Synovitis: Key Players in Osteoarthritis Progression.International journal of molecular sciences · 2024Review
- Article
- Tristetraprolin regulates the skeletal phenotype and osteoclastogenic potential through monocytic myeloid-derived suppressor cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- In vitro osteoclastogenesis assessment using murine myeloid-derived suppressor cells.Methods in cell biology · 2024Article
- Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms.Journal of bone oncology · 2023Review
- Review
- From Cells to Environment: Exploring the Interplay between Factors Shaping Bone Health and Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Bone Healing Gone Wrong: Pathological Fracture Healing and Non-Unions-Overview of Basic and Clinical Aspects and Systematic Review of Risk Factors.Bioengineering (Basel, Switzerland) · 2023Review
- The role of myeloid derived suppressor cells in musculoskeletal disorders.Frontiers in immunology · 2023Review
- Article
- Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.Diseases (Basel, Switzerland) · 2022Review
- Novel Preosteoclast Populations in Obesity-Associated Periodontal Disease.Journal of dental research · 2022Article
- Sarcopenia and bone health: new acquisitions for a firm liaison.Therapeutic advances in musculoskeletal disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Age-related alteration of the immune system with aging, or immunosenescence, plays a major role in several age-associated conditions, including loss of bone integrity. Studies over the past several years have clearly established the immune system is chronically activated with advanced aging, termed inflammaging, and is characterized by elevated levels of proinflammatory cytokines in response to physiological or environmental cues that essentially result in an arrested immune system that maintains a low-level state of activation. This age-associated inflammation impacts several biological systems including the innate immune system, where aging results in a skewing of the hematopoiesis toward the myeloid lineage, including the expansion of myeloid-derived suppressor cells (MDSCs). This heterogeneous population of myeloid cells classically displays immunosuppressive capacity but they also have the ability to directly differentiate into osteoclasts. This review explores the possibility of inflammaging to be involved in reduction of bone microarchitecture and loss of bone mass/strength through the expansion of MDSCs and the osteoclastogenic capacity and activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.